Editorially independent content, supported with advertising
05.12.22
How has reimbursement for common vitreoretinal procedures changed from 2011 to 2020? To find out, moderator Eric Nudleman, MD, PhD, hears from panelists John Miller, MD; Thanos Papakostas, MD; and Priya Vakharia, MD, as they discuss a recent piece on the topic published in the journal Ophthalmology. After reviewing the findings, the panel discusses the implications for reduced reimbursement in an era of improved efficiency and asks whether future innovation will allow patients to receive the same level of care even as reimbursement declines.
07.18.25
Diabetic Retinopathy Severity and Income StatusBen Young, MD; Phoebe Mellen, MD; and Jordan Deaner, MD
06.20.25
Photobiomodulation for Age-related Macular DegenerationModerator Barton Blackorby, MD; Hong-Uyen Hua, MD; and Louis Cai, MD
03.21.25
Rates of Ocular AEs After Faricimab InjectionMaura Di Nicola, MD; Sruthi Arepalli, MD; and Barton Blackorby, MD
12.19.24
Switching from Aflibercept to Faricimab in Wet AMD PatientsBen Young, MD, MS; Lediana Goduni, MD; and Joshua Uhr, MD,
11.21.24
New Retina Radio Journal Club w/ VBS: Does Metformin Reduce AMD Risk?Moderator Rebecca Soares, MD; Matt Starr, MD; and Nikisha Kothari, MD
10.17.24
New Retina Radio Journal Club with VBS: Pre-treatment with Chlorhexidine vs. Povidone-Iodine in Endophthalmitis PreventionMaura Di Nicola, MD; Sruthi Arepalli, MD; and Barton Blackorby, MD
09.17.24
New Retina Radio Journal Club w/ VBS: Risk of Death, Stroke, and MI After RAOKatherine Talcott, MD; Kyle Kovacs, MD; and Phoebe Mellen, MD
08.29.24
New Retina Radio Journal Club with VBS: Switching to Faricimab in Wet AMD Patients With a History of Anti-VEGF TherapyBen Young, MD, MS; Lediana Goduni, MD; and Josh Uhr, MD,
07.19.24
New Retina Radio Journal Club w/ VBS: Risk Factors for Switching from Bevacizumab to Aflibercept in Protocol ACRebecca Soares, MD; Matt Starr, MD; and Nikisha Kothari, MD
Show More